ArticleFrontiers in medicine2026
Pan-immune-inflammation value is a novel prognostic biomarker in pT2-4 gastric cancer.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives: Gastric cancer (GC) is a leading cause of cancer-related mortality worldwide and has a poor prognosis. Novel biomarkers are required to predict the survival of patients with this aggressive disease. Although the pan-immune-inflammation value (PIV) has been associated with outcomes in various malignancies, its prognostic role in GC remains unclear. Materials and methods: Clinical data of 793 patients with pT2-4 GC were retrospectively reviewed and analyzed. An optimal cutoff value was determined using receiver operating characteristic (ROC) curve analysis to stratify patients into high- and low-PIV groups. The prognostic performances of PIV and other immune-inflammatory biomarkers (IIBs) were compared using ROC analysis. Associations between the PIV and clinicopathological characteristics were also assessed. Kaplan-Meier survival curves were constructed for progression-free survival (PFS) and overall survival (OS). Univariate and multivariate Cox regression analyses were performed to determine independent prognostic factors. Results: The PIV demonstrated superior predictive value for survival compared to other peripheral blood-derived markers. High PIV values were significantly correlated with the Conclusion: This study established PIV as a significant and independent prognostic biomarker for pT2-4 GC. PIV exhibits a more sensitive predictive ability for the tumor burden and systemic inflammation than other evaluated IIBs, which provides potential clinical value for patients with pT2-4 GC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.